Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use

Diagnostic Microbiology and Infectious Disease

Volumn 87, Issue 3, 2017, Pages 286-288

  Martin, Isabella W ^a   Tonner, Rita ^b   Trivedi, Julie ^b   Miller, Heather ^a   Lee, Richard ^c   Liang, Xinglun ^d   Rotello, Leo ^b   Isenbergh, Elena ^b   Anderson, Jennifer ^b   Perl, Trish ^a   Zhang, Sean X ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d Tongji University School of Medicine   (China)

Author keywords

Fungal infection; Fungemia; Probiotic; Saccharomyces boulardii; Strain typing

Indexed keywords

ANTIBIOTIC AGENT; FLUCONAZOLE; PROBIOTIC AGENT; ANTIFUNGAL AGENT; FLORASULAM; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BLOOD CULTURE; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; DRUG CAPSULE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEVER; FUNGAL STRAIN; FUNGEMIA; GENOMICS; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOCOMPETENCE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYCOSIS; NONHUMAN; PROTEOMICS; RESPIRATORY TRACT DISEASE; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; SEPSIS; TACHYCARDIA; URINARY TRACT INFECTION; DIARRHEA; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTIFUNGAL AGENTS; DIARRHEA; FLUCONAZOLE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED; MYCOLOGICAL TYPING TECHNIQUES; PROBIOTICS; PYRIMIDINES; SACCHAROMYCES BOULARDII; SULFONAMIDES;

EID: 85008240111     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2016.12.004     Document Type: Article

References (10)

1. Cassone, M., Serra, P., Mondello, F., Girolamo, A., Scafetti, S., Pistella, E., et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 41 (2003), 5340–5343.
2. Ehrhardt, S., Guo, N., Hinz, R., Schoppen, S., May, J., Reiser, M., et al. Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis, 3, 2016 [ofw011].
3. Enache-Angoulvant, A., Hennequin, C., Invasive saccharomyces infection: a comprehensive review. Clin Infect Dis 41 (2005), 1559–1568.
4. Goldenberg, J.Z., Ma, S.S., Saxton, J.D., Martzen, M.R., Vandvik, P.O., Thorlund, K., et al. Probiotics for the prevention of Clostridium Difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev, 5, 2013, CD006095.
5. Hempel, S., Newberry, S., Ruelaz, A., Wang, Z., Miles, J.N., Suttorp, M.J., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess, 2011, 1–645.
6. McFarland, L.V., Systematic review and meta-analysis of saccharomyces boulardii in adult patients. World J Gastroenterol 16 (2010), 2202–2222.
7. Posteraro, B., Sanguinetti, M., Romano, L., Torelli, R., Novarese, L., Fadda, G., Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae. Int J Food Microbiol 103 (2005), 295–304.
8. Szajewska, H., Kolodziej, M., Systematic review with meta-analysis: saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 42 (2015), 793–801.
9. Videlock, E.J., Cremonini, F., Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther 35 (2012), 1355–1369.
10. Yi, S.H., Jernigan, J.A., McDonald, L.C., Prevalence of probiotic use among inpatients: a descriptive study of 145 U.S. hospitals. Am J Infect Control 44 (2016), 548–553.